After taking over Lancet, Cerba remains on the offensive on the continent
The leading biomedical company wants to accelerate the pace of its Covid-19 testing in Africa and continues to pursue its acquisition strategy.
Someone shares this article with you
▪ After taking over Lancet, Cerba remains on the offensive on the continent
▪ The leading biomedical company wants to accelerate the pace of its Covid-19 testing in Africa and continues to pursue its acquisition strategy.
▪ https://www.jeuneafriquebusinessplus.com/en/804556/apres-la-prise-de-lancet-cerba-toujours-a-loffensive-sur-le-continent/
02/06/2020 at 16h33, by Jeune Afrique Business+, updated 15/01/2021
“We’ve been negatively impacted by supply chain tensions in recent weeks,” Stéphane Carré told Jeune Afrique Business+. He is Chief Executive Officer of Cerba Lancet Africa (CLA), a subsidiary of Cerba Healthcare, one the largest laboratory company’s in Europe, with €850m in revenue in 2018.
To read the article and discover your subscription benefits
You are connected to your Jeune Afrique account but your Jeune Afrique Business+ subscription does not allow you to consult the English version. To update your subscription, contact us by clicking here.
Any questions ? contact us
Please get in touch with the Jeune Afrique Business+ team if you require any further information.
Email us : abonnements@jeuneafriquebusinessplus.com
Add JAB+ to your home screen
1. Click on 
at the bottom of your screen.
2. Click on 
to add JAB+ on the home screen.
3. Enter the name of the shortcut and confirm.